Topics

Roche Terminates Myostatin Inhibitor for DMD One Year After Pfizer Did the Same

19:00 EST 7 Nov 2019 | BioSpace

Roche intends to hold two global meetings with members of the DMD community to provide the stakeholders with as much information as possible.

Original Article: Roche Terminates Myostatin Inhibitor for DMD One Year After Pfizer Did the Same

NEXT ARTICLE

More From BioPortfolio on "Roche Terminates Myostatin Inhibitor for DMD One Year After Pfizer Did the Same"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...